Minerva Neurosciences | NERV - Ebitda


Minerva Neurosciences reported $-4.36M in EBITDA for its fiscal quarter ending in September of 2024.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Adma Biologics USD 73.59M 14.85M Dec/2025
ALKERMES USD 100.31M 21.24M Dec/2025
Alterity Therapeutics Limited AUD -7.72M 2.99M Jun/2023
AstraZeneca USD 5.67B 1.29B Mar/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Cipla INR 12.55B 6.4B Dec/2025
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -7.89M 536K Sep/2025
CSL USD 3.13B 1.17B Dec/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Grifols EUR 482.04M 7.04M Sep/2025
Halozyme Therapeutics USD 21.9M 226.34M Dec/2025
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
J&J USD 7.19B 2.32B Dec/2025
Merck USD 6.3B 2.09B Dec/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Novartis USD 5.3B 530M Mar/2026
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 756M 5.32B Dec/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 3.31B 3.65B Mar/2026
Takeda JPY 448.13B 173.98B Dec/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024